Influence
November 1, 2021

Regenstrief scientist highlights benefits of gene-specific approaches to colon cancer surveillance

Regenstrief Research Scientist Jennifer K. Maratt, M.D., M.S., co-authored a commentary in Gastroenterology about the benefits of gene-specific surveillance colonoscopy strategies for Lynch Syndrome, an inherited syndrome that increases the risk for colon cancer.

The editorial was published in conjunction with a paper from Columbia University. In that study, researchers created different surveillance strategies for each of the pathogenic variants linked to Lynch Syndrome. The strategies included varying starting ages for colonoscopies and surveillance intervals. They calculated each strategy’s cost-effectiveness in terms of colon cancer prevention and quality-adjusted life years. The best strategies varied based on the gene involved.

Dr. Maratt and co-author Joel Rubenstein, M.D., MSc, from the LTC Charles S. Kettles VA Medical Center and University of Michigan and concluded that based on this study, more colonoscopies might not always be the best approach. For some gene variants, less aggressive screening schedules might provide more value to patients by saving time and costs, while also yielding similar prevention rates. They state future studies are needed to understand if these strategies are feasible and acceptable to patients.

Dr. Maratt’s research focuses on colorectal cancer screening and surveillance and patient-centered approaches to reducing low-value care and optimizing appropriate care.

“Tailoring Colorectal Cancer Surveillance in Lynch Syndrome: More Is Not Always Better” is published in Gastroenterology.

About Jennifer K. Maratt, M.D., M.S.

In addition to her role as a research scientist at Regenstrief, Jennifer K. Maratt, M.D., M.S., is an assistant professor for the Division of Gastroenterology and Hepatology at Indiana University School of Medicine. She is also a practicing gastroenterologist at IU Health and the Richard L. Roudebush Veterans Affairs Medical Center.

Related News

image of a doctor consulting with a patient

Scalable approach could improve early detection of cognitive impairment in primary care

Regenstrief-led study evaluates how existing health data and patient-reported information could help clinicians identify individuals who need further assessmentEarly

Christopher Callahan, MD

Regenstrief Institute scientist named next president and CEO of Regenstrief Foundation 

Longtime Regenstrief investigator and former IU Center for Aging Research director will assume Foundation leadership in summer 2027.  Christopher

Rachel Patzer, PhD, MPH

Building trust in healthcare AI through data and evidence

As artificial intelligence rapidly transforms healthcare, innovation alone is not enough. Health systems need evidence that AI tools are

doctor using electronic health record

Data expertise helps researchers understand how clinical tools are used in real-world care

Regenstrief Data Services (RDS) provided critical health data and specialized expertise to support research examining clinical decision-support use across